4-(3-chloroanilino)quinazoline has been researched along with rtki cpd in 3 studies
*RTKI cpd: preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors [MeSH]
*RTKI cpd: preferentially inhibits human glioma cells expressing truncated rather than wild-type epidermal growth factor receptors [MeSH]
| Studies (4-(3-chloroanilino)quinazoline) | Trials (4-(3-chloroanilino)quinazoline) | Recent Studies (post-2010) (4-(3-chloroanilino)quinazoline) | Studies (rtki cpd) | Trials (rtki cpd) | Recent Studies (post-2010) (rtki cpd) |
|---|---|---|---|---|---|
| 8 | 0 | 2 | 41 | 0 | 21 |
| Protein | Taxonomy | 4-(3-chloroanilino)quinazoline (IC50) | rtki cpd (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.125 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.1152 | |
| Fructose-1,6-bisphosphatase 1 | Homo sapiens (human) | 1.3 | |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 2.7 | |
| Sodium-dependent serotonin transporter | Rattus norvegicus (Norway rat) | 0.56 | |
| Tyrosine-protein kinase ABL2 | Homo sapiens (human) | 0.125 | |
| Epidermal growth factor receptor | Mus musculus (house mouse) | 0.1 | |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | 0.56 | |
| MAP kinase-interacting serine/threonine-protein kinase 1 | Homo sapiens (human) | 0.53 | |
| Histamine H3 receptor | Rattus norvegicus (Norway rat) | 1.3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bridges, AJ; Cody, DR; Denny, WA; Fry, DW; Kraker, AJ; McMichael, A; Rewcastle, GW; Showalter, HD; Zhou, H | 1 |
| App, H; Chen, I; Chen, J; Gazit, A; Hirth, P; Levitzki, A; McMahon, G | 1 |
| Caflisch, A; Dey, F; Huang, D; Kolb, P | 1 |
3 other study(ies) available for 4-(3-chloroanilino)quinazoline and rtki cpd
| Article | Year |
|---|---|
Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor.
Topics: Aniline Compounds; Binding Sites; Blotting, Western; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Humans; Kinetics; Molecular Conformation; Molecular Structure; Phosphorylation; Protein Binding; Quinazolines; Structure-Activity Relationship; Tumor Cells, Cultured | 1996 |
Tyrphostins IV--highly potent inhibitors of EGF receptor kinase. Structure-activity relationship study of 4-anilidoquinazolines.
Topics: Aniline Compounds; ErbB Receptors; Phosphorylation; Protein Kinase C; Quinazolines; Staurosporine; Structure-Activity Relationship | 1996 |
Discovery of kinase inhibitors by high-throughput docking and scoring based on a transferable linear interaction energy model.
Topics: Humans; Models, Molecular; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Quantitative Structure-Activity Relationship; Static Electricity; Thermodynamics | 2008 |